Drugs / ACP-001
ACP-001
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01010425 | Nov 2009 → Feb 2010 | — | Ascendis Pharma A/S | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01947907 | Jul 2013 → Jul 2015 | — | Ascendis Pharma A/S | Completed | No outcome recorded |
| Phase 2 | NCT01247675 | Nov 2010 → May 2011 | pituitary deficiency | Ascendis Pharma A/S | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01947907 ↗ |
| Known as | TransCon growth hormone | “TransCon growth hormone (GH) is a sustained-release inactive prodrug consisting of unmodified GH transiently bound to an inert carrier molecule designed to release fully active...” PMID 29273485 ↗ Dec 2017 |
| Known as | TransCon hGH | “ACP-001 (TransCon hGH)” NCT01247675 ↗ |
| Known as | TransCon PEG hGH | “ACP-001 (TransCon PEG hGH)” NCT01010425 ↗ |
| Modality | Protein / enzyme biologic | “long-acting recombinant sustained-release human GH prodrug” PMID 28201598 ↗ May 2017 |
| Route | Subcutaneous | “Once weekly subcutaneous injection of ACP-001” NCT01247675 ↗ |